TY  -  
T1  - The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes 
SN  -  /  
UR  - http://hdl.handle.net/10138/325991 
T3  -  
A1  - Wilson, Jonathan M.; Nikooienejad, Amir; Robins, Deborah A.; Roell, William C.; Riesmeyer, Jeffrey S.; Haupt, Axel; Duffin, Kevin L.; Taskinen, Marja-Riitta; Ruotolo, Giacomo 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Aim To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc in available samples from the same study. Materials and Methods Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo. Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measur... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - incretin therapy; type 2 diabetes; TRIGLYCERIDE-RICH LIPOPROTEINS; APOLIPOPROTEIN C-III; APOC-III; POLYPEPTIDE RECEPTOR; HEPATIC LIPASE; LIPIDS; LIRAGLUTIDE; MECHANISMS; OUTCOMES; THERAPY; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -